Crossref
A Phase I Study Of The Combination Of TZT-1027 (Soblidotin) And Gemcitabine Administered On Day 1 And 8 Every Three Weeks To Patients With Advanced Or Metastatic Solid Tumors
The Internet Journal of Oncology · 2008
DOI: 10.5580/15d9 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Internet Journal of Oncology, 2008.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2008). A Phase I Study Of The Combination Of TZT-1027 (Soblidotin) And Gemcitabine Administered On Day 1 And 8 Every Three Weeks To Patients With Advanced Or Metastatic Solid Tumors. The Internet Journal of Oncology. https://doi.org/10.5580/15d9
Vancouver
A Phase I Study Of The Combination Of TZT-1027 (Soblidotin) And Gemcitabine Administered On Day 1 And 8 Every Three Weeks To Patients With Advanced Or Metastatic Solid Tumors. The Internet Journal of Oncology. 2008. doi:10.5580/15d9
BibTeX
@article{euvimed2008,
title = {A Phase I Study Of The Combination Of TZT-1027 (Soblidotin) And Gemcitabine Administered On Day 1 And 8 Every Three Weeks To Patients With Advanced Or Metastatic Solid Tumors},
journal = {The Internet Journal of Oncology},
year = {2008},
doi = {10.5580/15d9}
}
EUVIMED